Journal of Oncology · 2019 · 30 citations · 27 references
PharmacyOncologyPharmacologyDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer NanomedicineGlioblastomaMtor Inhibitor TherapyNanoparticle DesignTargeted Cancer TherapyTargeted TherapyCell Cycle AnalysisCytotoxicity AssaysEverolimus TreatmentGlioblastoma Drug TherapyGlioblastoma Targeted TherapyNanoparticle CytotoxicityScavenger Receptor Class B Type 1Tumor-targeted Drug Delivery
PURPOSE: . These studies involve the evaluation of reconstituted high density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for the drug, mammalian Target of Rapamycin (mTOR) inhibitor Everolimus (EVR) to GBM cells. Cytotoxicity studies and assessment of downstream effects, including apoptosis, migration, and cell cycle events, were probed, in relation to the expression of scavenger receptor B type 1 (SR-B1) by GBM cells. RESULTS: Findings from cytotoxicity studies indicate that the rHDL/EVR formulation was 185 times more potent than free EVR against high SR-B1 expressing cell line (LN 229). Cell cycle analysis revealed that rHDL/EVR treated LN229 cells had a 5.8 times higher apoptotic cell population than those treated with EVR. The sensitivity of GBM cells to EVR treatment was strongly correlated with SR-B1 expression. CONCLUSIONS: These studies present strong proof of concept regarding the efficacy of delivering EVR and likely other agents, via a biocompatible transport system, targeted to the SR-B1 receptor that is upregulated in most cancers, including GBM. Targeting the SR-B1 receptor could thus lead to effective personalized therapy of GBM.
27
High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme
Padma Kadiyala, Dan Li, Fernando M. Núñez et al. · ACS Nano · 2019 · 213 citations
Pharmacy, Oncology, Pharmacology +17
Daniel Goti, Andelko Hrzenjak, Sanja Levak‐Frank et al. · Journal of Neurochemistry · 2001 · 143 citations
Biomimetic, synthetic HDL nanostructures for lymphoma
Shuo Yang, Marina G. Damiano, Heng Zhang et al. · Proceedings of the National Academy of Sciences · 2013 · 130 citations · Full text
Pharmacy, Oncology, Pharmacology +17